Back

Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling

Walter, D. M.; Gladstein, A. C.; Doerig, K. R.; Natesan, R.; Baskaran, S. G.; Gudiel, A. A.; Adler, K. M.; Acosta, J. O.; Wallace, D. C.; Asangani, I. A.; Feldser, D. M.

2022-10-06 cancer biology
10.1101/2022.10.06.511146 bioRxiv
Show abstract

SETD2 is a tumor suppressor that is frequently inactivated in several cancer types. The mechanisms through which SETD2 inactivation promotes cancer are unclear, and whether targetable vulnerabilities exist in these tumors is unknown. Here we identify heightened mTORC1-associated gene expression programs and functionally higher levels of oxidative metabolism and protein synthesis as prominent consequences of Setd2 inactivation in KRAS-driven mouse models of lung adenocarcinoma. Blocking oxidative respiration and mTORC1 signaling abrogates the high rates of tumor cell proliferation and tumor growth specifically in SETD2-deficient tumors. Our data nominate SETD2 deficiency as a functional marker of sensitivity to clinically actionable therapeutics targeting oxidative respiration and mTORC1 signaling.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Oncogene
○ 85 papers in training set
Top 0.1%
26.3%
Similar papers in this journal
2
Cancer Research
● 130 papers in training set
Top 0.1%
12.8%
Similar papers in this journal
3
Cancer Letters
○ 35 papers in training set
Top 0.1%
6.7%
Similar papers in this journal
4
eLife
● 5828 papers in training set
Top 23%
5.4%
Similar papers in this journal
50% of probability mass above
5
Nature Communications
○ 5641 papers in training set
Top 31%
4.3%
Similar papers in this journal
6
Molecular Cancer Research
● 49 papers in training set
Top 0.2%
4.0%
7
Cancers
○ 213 papers in training set
Top 2%
2.6%
8
Cancer Research Communications
● 51 papers in training set
Top 0.9%
1.7%
9
Cancer Discovery
● 66 papers in training set
Top 1%
1.7%
10
Cell Reports
○ 1498 papers in training set
Top 20%
1.7%
11
Science Advances
● 1243 papers in training set
Top 21%
1.7%
12
Cell Death & Differentiation
○ 48 papers in training set
Top 0.6%
1.5%
13
Clinical Cancer Research
● 64 papers in training set
Top 1%
1.4%
14
Journal of Clinical Investigation
● 179 papers in training set
Top 4%
1.1%
15
EMBO Reports
○ 263 papers in training set
Top 5%
1.1%
16
JCI Insight
● 277 papers in training set
Top 6%
1.1%
17
Molecular Metabolism
○ 112 papers in training set
Top 1%
1.1%
18
Genome Medicine
○ 183 papers in training set
Top 4%
1.0%
19
Molecular Oncology
○ 55 papers in training set
Top 1%
1.0%
20
Molecular Cancer
○ 16 papers in training set
Top 0.2%
1.0%
21
PLOS Genetics
● 862 papers in training set
Top 11%
1.0%
22
Cell Death & Disease
147 papers in training set
Top 3%
0.9%
23
Oncogenesis
○ 12 papers in training set
Top 0.4%
0.8%
24
Genes & Development
● 90 papers in training set
Top 2%
0.8%
25
Cancer Gene Therapy
○ 11 papers in training set
Top 0.1%
0.8%
26
Redox Biology
○ 70 papers in training set
Top 1%
0.8%
27
Journal of Experimental Medicine
● 119 papers in training set
Top 3%
0.8%
28
Molecular and Cellular Biology
○ 47 papers in training set
Top 0.8%
0.8%
29
BMC Cancer
○ 67 papers in training set
Top 2%
0.8%
30
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 45%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.